Updates are available Correction dated 2018-02-28
Click to view Correction: https://0-doi-org.brum.beds.ac.uk/10.1186/s12889-018-5173-7
-
Authors
Zablotska, Iryna B. http://orcid.org/0000-0003-1456-2197
,
Selvey, Christine
Guy, Rebecca
Price, Karen
Holden, Jo
Schmidt, Heather-Marie
McNulty, Anna
Smith, David
Jin, Fengyi
Amin, Janaki
Cooper, David A.
Grulich, Andrew E.
-
Funding
Funding for this research was provided by:
Department of Health, New South Wales Government
-
More Information
Article History
Received: 30 June 2017
Accepted: 21 December 2017
First Online: 2 February 2018
Change Date: 28 February 2018
Change Type: Correction
Change Details: After publication of the article [1], it has been brought to our attention that one of the members of the EPIC-NSW study group has had their name spelt incorrectly in the acknowledgements. The article mentions “Muhammad Hammoud” when in fact the correct spelling is “Mohamed Hammoud”.
Ethics approval and consent to participate
: The study protocol is approved by the St. Vincent’s Hospital, Sydney, Australia HREC (primary review, protocol number 1511; reference number HREC/15/SVH/436) and ACON HREC (reference number RERC2015/23). TheExternalRef removedidentifying number is NCT02870790. Site-specific assessments are obtained from each public health service’s Research Office. The design and implementation of this study follows The Declaration of Helsinki and European Committee for Proprietary Medicinal Products/ International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (CPMP/ICH) Guidelines for Good Clinical Practice. All EPIC-NSW participants have provided written informed consent to participate in the study.
: Not applicable
: DAC has received honoraria from Gilead Sciences, ViiV and Merck Sharp & Dohme. AG has received research funding from BioCSL Ltd., Viiv and Gilead Sciences, as well as conference travel funding and honoraria for educational presentations from Merck. IZ has received funding and supply of the study medication from Gilead Sciences. DS has received funding to attend local (within Australia) educational events from Gilead, and funding from ViiV, BMS, Merck, Roche, Boehringer Ingleheim and Gilead to hold local education events for health practitioners. CS, H-MS, JA, FJ, JH, KP, RG have no conflicts of interest to declare.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
